Malignant Head and Neck Mucosal Neoplasm — Variants & evidence

Malignant Head and Neck Mucosal Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

4 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items (4 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E1
Vemurafenib	Laryngeal Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5962 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
GAS6 EXPRESSION1
(prognostic)	Oral Cavity Squamous Cell CarcinomaALIAS	Prognostic	B	Supports Poor Outcome	4	accepted	EID1657 128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with… (full text at CIViC) PMID 26207647 · Jiang et al., 2015 · Open in CIViC	civic
LGR5 delta51
(prognostic)	Oral Cavity Squamous Cell CarcinomaALIAS	Prognostic	B	Supports Poor Outcome	4	submitted	EID9621 In a clinical trial including 78 patients, expression of delta5 is significantly associated with decreased OS (p = 0.02) and DFS (p = 0.01) by multivariate analysis. PMID 30770730 · Rot et al., 2019 · Open in CIViC	civic
TP53 DNA Binding Domain Mutation1
(prognostic)	Oral Cavity Squamous Cell CarcinomaALIAS	Prognostic	B	Supports Poor Outcome	4	accepted	EID641 Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutati… (full text at CIViC) PMID 12509970 · Yamazaki et al., 2003 · Open in CIViC	civic

Data updated 15 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.